The DOI matches its Crossref record.
A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.
Open accessAbstract
Daunorubicin (DNR) has been conjugated to succinylated serum albumin by an amide bond joining the amino group of the drug and a carboxyl side chain of the protein either directly or with the intercalation of a peptide spacer arm varying from one to four amino acids. During in vitro incubation with lysosomal hydrolases, intact DNR could be released extensively only from conjugates prepared with a tri- or tetrapeptide spacer arm. These latter conjugates remained very stable in the presence of serum. When tested in vivo against the intraperitoneal form of L1210 leukemia, the conjugates in which DNR was linked to serum albumin directly or via one amino acid were completely inactive but the conjugate with a dipeptide spacer arm was not more active than free DNR. In parallel with the in vitro studies, the best therapeutic results were obtained with the conjugates formed with tri- and tetrapeptidic spacer arms; they were much more active than DNR, inducing a high percentage of long-term survivors. Thus, use of a tri- or tetrapeptide spacer arm is essential to obtain DNR-protein conjugates that remain stable in serum and from which DNR can be released through the action of lysosomal hydrolases. The in vivo results suggest, moreover, that these conjugates are endocytosed by L1210 cells and that DNR is released intracellularly after digestion by lysosomal enzymes. This conjugation method can be applied to other drugs possessing a free amino group and to various potential carriers, such as antibodies, polypeptide hormones, and glycoproteins, that have amino or carboxyl side chains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00134-4 · Cited by 662
Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo
Maeda, H., Seymour, L. W., & Miyamoto, Y. (1992) · Bioconjugate Chemistry · doi:10.1021/bc00017a001 · Cited by 560
Cancer nanomedicines: So many papers and so few drugs!
Venditto, V. J., & Szoka, F. C. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.038 · Cited by 537
Multifunctional dendritic polymers in nanomedicine: opportunities and challenges
Khandare, J., Calderón, M., Dagia, N. M., & Haag, R. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15242d · Cited by 418
Duncan, R., & Richardson, S. C. W. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300293n · Cited by 332
Soluble synthetic polymers as potential drug carriers
Duncan, R., & Kopeček, J. (1984) · Advances in Polymer Science · doi:10.1007/3-540-12796-8_10 · Cited by 318
Polymeric Antitumor Agents on a Molecular and on a Cellular Level?
Gros, L., Ringsdorf, H., & Schupp, H. (1981) · Angewandte Chemie International Edition in English · doi:10.1002/anie.198103051 · Cited by 318
Polymer conjugates with anticancer activity
Putnam, D., & Kopeček, J. (1995) · Advances in Polymer Science · doi:10.1007/3540587888_14 · Cited by 315
Prodrug-based intracellular delivery of anticancer agents
Bildstein, L., Dubernet, C., & Couvreur, P. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.12.005 · Cited by 310
Watersoluble polymers in medicine
Bader, H., Ringsdorf, H., & Schmidt, B. (1984) · Die Angewandte Makromolekulare Chemie · doi:10.1002/apmc.1984.051230121 · Cited by 291
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
Dubowchik, G. M., & Walker, M. A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00018-2 · Cited by 277
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
Schally, A., & Nagy, A. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410001 · Cited by 271
Tugyi, R., Uray, K., Iván, D., Fellinger, E., Perkins, A., & Hudecz, F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407677102 · Cited by 264
Targeted drug conjugates: principles and progress
Garnett, M. C. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00227-7 · Cited by 262
A Hyaluronic Acid−Taxol Antitumor Bioconjugate Targeted to Cancer Cells
Luo, Y., Ziebell, M. R., & Prestwich, G. D. (2000) · Biomacromolecules · doi:10.1021/bm000283n · Cited by 261
Metadata
- Authors
- Trouet, A., Masquelier, M., Baurain, R., & Deprez-De Campeneere, D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1982-01
- Volume
- 79
- Issue
- 2
- Pages
- 626-629
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2049348498
- Cited by
- 233
- References
- 0
- FWCI
- 12.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.